310 related articles for article (PubMed ID: 25956172)
1. Practical problems with clinical guidelines for breast cancer prevention based on remaining lifetime risk.
Quante AS; Whittemore AS; Shriver T; Hopper JL; Strauch K; Terry MB
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 25956172
[TBL] [Abstract][Full Text] [Related]
2. Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium.
Fischer C; Kuchenbäcker K; Engel C; Zachariae S; Rhiem K; Meindl A; Rahner N; Dikow N; Plendl H; Debatin I; Grimm T; Gadzicki D; Flöttmann R; Horvath J; Schröck E; Stock F; Schäfer D; Schwaab I; Kartsonaki C; Mavaddat N; Schlegelberger B; Antoniou AC; Schmutzler R;
J Med Genet; 2013 Jun; 50(6):360-7. PubMed ID: 23564750
[TBL] [Abstract][Full Text] [Related]
3. 10-year performance of four models of breast cancer risk: a validation study.
Terry MB; Liao Y; Whittemore AS; Leoce N; Buchsbaum R; Zeinomar N; Dite GS; Chung WK; Knight JA; Southey MC; Milne RL; Goldgar D; Giles GG; McLachlan SA; Friedlander ML; Weideman PC; Glendon G; Nesci S; Andrulis IL; John EM; Phillips KA; Daly MB; Buys SS; Hopper JL; MacInnis RJ
Lancet Oncol; 2019 Apr; 20(4):504-517. PubMed ID: 30799262
[TBL] [Abstract][Full Text] [Related]
4. Validating the IBIS and BOADICEA Models for Predicting Breast Cancer Risk in the Iranian Population.
Ghoncheh M; Ziaee F; Karami M; Poorolajal J
Clin Breast Cancer; 2017 Jun; 17(3):e113-e118. PubMed ID: 28216418
[TBL] [Abstract][Full Text] [Related]
5. Performance of BRCA1/2 mutation prediction models in male breast cancer patients.
Moghadasi S; Grundeken V; Janssen LAM; Dijkstra NH; Rodríguez-Girondo M; van Zelst-Stams WAG; Oosterwijk JC; Ausems MGEM; Oldenburg RA; Adank MA; Blom EW; Ruijs MWG; van Os TAM; van Deurzen CHM; Martens JWM; Schroder CP; Wijnen JT; Vreeswijk MPG; van Asperen CJ
Clin Genet; 2018 Jan; 93(1):52-59. PubMed ID: 28589637
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the BOADICEA risk assessment model in women with a family history of breast cancer.
Ståhlbom AK; Johansson H; Liljegren A; von Wachenfeldt A; Arver B
Fam Cancer; 2012 Mar; 11(1):33-40. PubMed ID: 22124624
[TBL] [Abstract][Full Text] [Related]
7. Evaluating BRCA mutation risk predictive models in a Chinese cohort in Taiwan.
Hung FH; Wang YA; Jian JW; Peng HP; Hsieh LL; Hung CF; Yang MM; Yang AS
Sci Rep; 2019 Jul; 9(1):10229. PubMed ID: 31308460
[TBL] [Abstract][Full Text] [Related]
8. Population frequencies of pathogenic alleles of BRCA1 and BRCA2: analysis of 173 Danish breast cancer pedigrees using the BOADICEA model.
Terkelsen T; Christensen LL; Fenton DC; Jensen UB; Sunde L; Thomassen M; Skytte AB
Fam Cancer; 2019 Oct; 18(4):381-388. PubMed ID: 31435815
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
[TBL] [Abstract][Full Text] [Related]
10. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance.
Quante AS; Whittemore AS; Shriver T; Strauch K; Terry MB
Breast Cancer Res; 2012 Nov; 14(6):R144. PubMed ID: 23127309
[TBL] [Abstract][Full Text] [Related]
11. Prospective validation of the breast cancer risk prediction model BOADICEA and a batch-mode version BOADICEACentre.
MacInnis RJ; Bickerstaffe A; Apicella C; Dite GS; Dowty JG; Aujard K; Phillips KA; Weideman P; Lee A; Terry MB; Giles GG; Southey MC; Antoniou AC; Hopper JL
Br J Cancer; 2013 Sep; 109(5):1296-301. PubMed ID: 23942072
[TBL] [Abstract][Full Text] [Related]
12. Accuracy of Risk Prediction Models for Breast Cancer and
Kenan ES; Friger M; Shochat-Bigon D; Schayek H; Bernstein-Molho R; Friedman E
Anticancer Res; 2018 Aug; 38(8):4557-4563. PubMed ID: 30061222
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer risk prediction accuracy in Jewish Israeli high-risk women using the BOADICEA and IBIS risk models.
Laitman Y; Simeonov M; Keinan-Boker L; Liphshitz I; Friedman E
Genet Res (Camb); 2013 Dec; 95(6):174-7. PubMed ID: 24506973
[TBL] [Abstract][Full Text] [Related]
14. Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
Antoniou AC; Hardy R; Walker L; Evans DG; Shenton A; Eeles R; Shanley S; Pichert G; Izatt L; Rose S; Douglas F; Eccles D; Morrison PJ; Scott J; Zimmern RL; Easton DF; Pharoah PD
J Med Genet; 2008 Jul; 45(7):425-31. PubMed ID: 18413374
[TBL] [Abstract][Full Text] [Related]
15. Comparing 5-Year and Lifetime Risks of Breast Cancer using the Prospective Family Study Cohort.
MacInnis RJ; Knight JA; Chung WK; Milne RL; Whittemore AS; Buchsbaum R; Liao Y; Zeinomar N; Dite GS; Southey MC; Goldgar D; Giles GG; Kurian AW; ; Andrulis IL; John EM; Daly MB; Buys SS; Phillips KA; Hopper JL; Terry MB
J Natl Cancer Inst; 2021 Jun; 113(6):785-791. PubMed ID: 33301022
[TBL] [Abstract][Full Text] [Related]
16. Family history of cancer and cancer risks in women with BRCA1 or BRCA2 mutations.
Metcalfe K; Lubinski J; Lynch HT; Ghadirian P; Foulkes WD; Kim-Sing C; Neuhausen S; Tung N; Rosen B; Gronwald J; Ainsworth P; Sweet K; Eisen A; Sun P; Narod SA;
J Natl Cancer Inst; 2010 Dec; 102(24):1874-8. PubMed ID: 21098759
[TBL] [Abstract][Full Text] [Related]
17. Probability estimation models for prediction of BRCA1 and BRCA2 mutation carriers: COS compares favourably with other models.
Roudgari H; Miedzybrodzka ZH; Haites NE
Fam Cancer; 2008; 7(3):199-212. PubMed ID: 18097771
[TBL] [Abstract][Full Text] [Related]
18. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
[TBL] [Abstract][Full Text] [Related]
19. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry.
Pal Choudhury P; Brook MN; Hurson AN; Lee A; Mulder CV; Coulson P; Schoemaker MJ; Jones ME; Swerdlow AJ; Chatterjee N; Antoniou AC; Garcia-Closas M
Breast Cancer Res; 2021 Feb; 23(1):22. PubMed ID: 33588869
[TBL] [Abstract][Full Text] [Related]
20. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
